Replies to post #3126 on NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Maybe only a fraction of patients are PD-L1 Positive.

On the animation that you pointed me toward, it was stated that almost all cancers have PD-L1 expression (if that is the right word). On another, more recent write-up on recent clinical results for PD-L1 blockers, they state that half of the patients were PD-L1 negative and that the PD-L1 blocking therapies did not work very well on that large subset.

So PD-L1 blockers are not a panacea. If DCVax-L passes, as I expect, but is also not a panacea, as it probably isn't, then maybe the combination of the two will prove to be so. It could be that only a fraction of DCVax-L patients would need the PD-L1 blockers, and that fraction could be detected before therapy starts.

Someone on this or our sister blog has repeatedly talked about a likely complementary therapy / drug for DCVax-L. Maybe these PD-L1 blockers were what he/she was talking about.